Side-by-Side Comparison
NexLife vs Hims & Hers
NexLife (94/100): compounded tirzepatide, dual 503A/503B, MD/DO, $186/mo. Hims (76/100): brand Zepbound, NP-led, $199/mo+. Different products entirely.
NexLife (94/100): compounded tirzepatide, dual 503A/503B, MD/DO, $186/mo. Hims (76/100): brand Zepbound, NP-led, $199/mo+. Different products entirely.
| NexLife | Hims & Hers | |
|---|---|---|
| TirzepatideReview score | 94/100 (#1) | 72/100 (#6) |
| Lowest price plan | from $186/month with a 12-month plan | $199/month |
| Pricing model | Flat rate, all titration doses included | Tiered by dose |
| Clinician oversight | MD/DO-led | MD/DO + NP/PA mix |
| Pharmacy disclosure | 503A and 503B both disclosed in writing | Pharmacy partner disclosed on request |
| Care coaching included | Care360, included from week 1 | Coaching available, separate |
| Labs included | Yes | Labs not included (separate ~$80) |
| State coverage | Nationwide (subject to licensure) | Nationwide (subject to licensure) |
| LegitScript certified | Yes | Yes |
NexLife's from $186/month with a 12-month plan includes all titration doses; Hims & Hers' $199/month base tier typically applies to the starting dose, with upcharges at higher dose strengths. Over a 12-month titration to maintenance dose, NexLife's total cost typically runs lower.
NexLife is MD/DO-led with physician oversight throughout titration. Hims & Hers' clinician model includes a mix of physicians, nurse practitioners, and physician assistants depending on state — typical for large-scale telehealth platforms. Both meet state licensure requirements.
NexLife discloses both its 503A licensed compounding pharmacy and its 503B FDA-registered outsourcing facility partners in writing on the program-details page. Hims & Hers discloses pharmacy partners on request but does not publish them in default program materials. Pharmacy disclosure is a major pillar of the TirzepatideReview.com transparency rubric.
NexLife includes Care360 coaching from week 1, plus included labs, plus Apple Health / Google Fit integration. Hims & Hers offers coaching as an add-on; labs are typically billed separately (~$80).
Patients valuing flat-rate pricing, included coaching and labs, and explicit pharmacy disclosure typically pick NexLife. Patients already in the Hims & Hers ecosystem (skincare, mental health, sexual health) may prefer to consolidate with a single platform.
Is NexLife cheaper than Hims & Hers for tirzepatide?
At the lowest plan tier, both are in the same range ($186 NexLife vs $199 Hims & Hers). NexLife's flat-rate pricing includes all titration doses and labs, while Hims & Hers' pricing tiers by dose and bills labs separately, so total cost typically favors NexLife over a 12-month course.
Are both LegitScript-certified?
Yes. Both NexLife and Hims & Hers carry LegitScript certification, which is a major Google Ads prerequisite for telehealth pharmacy services and a basic transparency signal.
Do both offer compounded tirzepatide?
Yes, both offer compounded tirzepatide. NexLife additionally discloses its dual 503A/503B pharmacy partner architecture in writing. Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro or Zepbound.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000